Bridgeway Capital Management’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Bridgeway Capital Management’s Portfolio AYLA Stock Details AYLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-56,900	Closed	-$23.9K	–	1465
2022 Q4	$23.9K	Sell	56,900 -25,000	-31%	-$16.2K	﹤0.01%	1333
2022 Q3	$82K	Hold	81,900	–	–	﹤0.01%	1309
2022 Q2	$89K	Hold	81,900	–	–	﹤0.01%	1241
2022 Q1	$326K	Buy	81,900 +3,900	+5%	+$20.3K	0.01%	1049
2021 Q4	$664K	Buy	78,000 +25,000	+47%	+$248K	0.01%	908
2021 Q3	$601K	Buy	53,000 +21,038	+66%	+$252K	0.01%	984
2021 Q2	$326K	Sell	31,962 -3,038	-9%	-$31.2K	0.01%	1192
2021 Q1	$382K	Buy	+35,000	New	+$500K	0.01%	1172

Bridgeway Capital Management's AYLA Position: Q1 2023 in Review

Bridgeway Capital Management sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q1 2023, closing a stake of 56,900 shares — an estimated $23.9K sold.

Bridgeway Capital Management first reported a position in AYLA in Q1 2021 and held it in 8 quarters. The position peaked at $664K in Q4 2021. 0 funds tracked by Wall St. Rank hold AYLA as of Q1 2023.

Bridgeway Capital Management reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Bridgeway Capital Management sold 56,900 Ayala Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $23.9K.
Bridgeway Capital Management first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Bridgeway Capital Management's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $664K in Q4 2021.
0 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.